Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07820930 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation

Name: A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation — clinical trial record (NCT07820930)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ReDEFINE-AF

StatusNot Yet Recruiting

PhaseNot applicable

SponsorBoston Scientific Corporation

Started2026-11

View on ClinicalTrials.gov ↗

Boston Scientific Corporation

92 trials monitored

See 9 trials at risk

Atrial Fibrillation

1,126 trials monitored

See 49 trials at risk

The goal of the ReDEFINE-AF Clinical Study is to evaluate the safety and effectiveness of the FARAFLEX™ Mapping and Pulsed Field Ablation System with electrographic flow mapping in subjects undergoing repeat ablation for atrial fibrillation (AF).

Trial Details

NCT Number	NCT07820930
Lead Sponsor	Boston Scientific Corporation
Conditions	Atrial Fibrillation (AF), Persistent Atrial Fibrillation (PersAF), Paroxysmal Atrial Fibrillation (PAF)
Enrollment	650 participants
Start Date	2026-11
Primary Completion	2029-07 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-28